
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 6-K

**REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934**

For the month of **March 2016**

Commission File Number **001-36187**

EVOGENE LTD.

(Translation of Registrant's Name into English)

**13 Gad Feinstein Street
Park Rehovot P.O.B 2100
Rehovot 7612002 Israel**

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒

Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____

CONTENTS

On March 15, 2016, Evogene Ltd., or the Company, held a Special General Meeting of Shareholders, or the Meeting, at its principal executive offices in Rehovot, Israel. At the Meeting, at which a quorum was present, the proposal on the agenda was duly approved. A description of the proposal can be found in the Company's proxy statement with respect to the Meeting, which was attached as Exhibit 99.1 to the Company's Report of Foreign Private Issuer, furnished to the Securities and Exchange Commission on February 4, 2016.

A notice announcing the results of the Meeting is appended to this report as Exhibit 99.1.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

EVOGENE LTD.
(Registrant)

By: /s/ Eyal Leibovitz

Eyal Leibovitz
Chief Financial Officer

Date: March 16, 2016

EXHIBIT INDEX

EXHIBIT NO. DESCRIPTION

99.1. A notice announcing Results of Special General Meeting of Shareholders

Notice of Results of Special General Meeting of Shareholders

Evogene Ltd., or the Company, announced today that the proposal submitted to Shareholder approval at its Special General Meeting of Shareholders, held on March 15, 2016 in Rehovot, Israel, or the Meeting, was duly approved. At the Meeting, shareholders of the Company approved the following by the requisite majority under the Company's articles of association and the Israeli Companies Law, 5799-1999:

Adoption of a U.S. Addendum to Evogene Ltd. 2013 Share Option Plan, or the 2013 Plan, under which incentive stock options may be granted to our U.S. subsidiary employees and to any other employees of any U.S. affiliate of the Company that may be incorporated in the future in accordance with the U.S. Internal Revenue Code of 1986, as amended.

March 16, 2016
